Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

S.E. Grimm*, B. Wijnen, R. Riemsma, D. Fayter, N. Armstrong, C. Ahmadu, L. Brandts, K. Misso, J.R. Kirwan, J. Kleijnen, M.A. Joore

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)1397-1410
Number of pages14
JournalPharmacoeconomics
Volume39
Issue number12
Early online date27 Aug 2021
DOIs
Publication statusPublished - Dec 2021

Keywords

  • MODIFYING ANTIRHEUMATIC DRUGS
  • TOCILIZUMAB

Cite this